Edgar Filing: NEKTAR THERAPEUTICS - Form 4

	HERAPEUTICS										
Form 4	7 2015										
September 1									OMB A	PPROVAL	
				CURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						3235-0287	
Check th if no lon subject t Section Form 4 o Form 5 obligatio may con <i>See</i> Instr 1(b).	ger o 16. or Filed pur ons tinue.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							Estimated burden hol response	urs per	
(Print or Type	Responses)										
KUEBLER CHRISTOPHER A Sy N			2. Issuer Name and Ticker or Trading Symbol NEKTAR THERAPEUTICS [NKTR]				ng	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
	. , ,	Middle) SION		of Earliest T Day/Year) 2015	ransaction			X Director Officer (giv below)	ve title0tl below)	% Owner her (specify	
File				4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
	NCISCO, CA 941							Person		1 0	
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Secu	rities A	cquired, Disposed	of, or Beneficia	ally Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, any (Month/Day/Year)		Date, if	Code Disposed of (D)			Securities	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect			
Reminder: Ret	port on a separate line	e for each els	ass of sec					or indirectly			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	\$ 12.8	09/15/2015		А	12,500	<u>(1)</u>	09/14/2023	Common Stock	12,500
Restricted Stock Unit	<u>(2)</u>	09/15/2015		А	15,000	(3)	09/14/2023	Common Stock	15,000

Edgar Filing: NEKTAR THERAPEUTICS - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
			Officer	Other			
KUEBLER CHRISTOPHER A C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUT SAN FRANCISCO, CA 94158	Х						
Signatures							
Gilbert M. Labrucherie, Jr., Attorney-in-Fact	09/17	7/2015					
**Signature of Reporting Person	I	Date					

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) This option was granted on September 15, 2015 and vests in equal monthly installments over the one-year period following the grant date.
- (2) Each restricted stock unit represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock.

(3) This restricted stock unit award vests in full one year following the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.